home :
resources [
videos ::
patient education ::
prostate fax ::
publications ::
links ::
vitamin order form :: ]
BIBLIOGRAPHY:
Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R,Long-Term Outcome in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone. Journal of Urology Vol. 173: xxx 2005.
Guess B, Scholz M, Strum S, Lam R, Johnson H, Jennrich R,: Modified Citrus Pectin Increases the Prostate-Specific Antigen Doubling Time in Men with Prostate Cancer. Prostate Cancer and Prostatic Diseases Vol. 6: 301-304 2003.
Guess, B., Jennrich, R., Johnson, H., Redheffer, R., Scholz, M., Using Splines to Detect Changes in PSA Doubling Times. Prostate Vol. 54 #2: 88-94, 2003.
Scholz, M. Prostate Cancer Battle: Its Strictly Your Decision Chapter #11 “New Approaches to Prostate Cancer Treatment 1st Books Library March 2002.
Scholz, M. Prostate Cancer Battle: Its Strictly Your Decision Chapter #10 “Early Hormone Blockade for Men Suitable for Local Therapy” 1st Books Library March 2002
Scholz, M., Lam, R., Guess, B., Anti-androgen Monotherapy for Prostate Cancer. PAACT Cancer Communication Letter Volume 18 #2
Scholz, M. Strum, S. Berrios, F. Leibowitz, B. Guess, B. Low-Dose Weekly Docetaxel in Elderly Men with Prostate Cancer. Advances in Prostate Cancer Vol. 5, No. 3 2001
Guess, B. Scholz, M. Re: Failure to Achieve Castrate Levels of Testosterone During Luteinizing Hormone Releasing Hormone Agonist Therapy: The Case for Monitoring Serum Testosterone and A Treatment Decision Algorithm J. Urol., Vol. 164: 726-729, 2000
Scholz, M., Strum, B. PSA Nadir after starting Hormone Blockade Letter to the Editor J. Urol., Vol. 162: 293-306, 1999
Strum, S. Scholz, M. McDermed, J. Intermittent Androgen Deprivation in Prostate Cancer Patients; Factors Predictive of Prolonged Time off Therapy The Oncologist Vol. 5 2000
Scholz M.C., Strum S.B. Recovery of Erectile Function while on Hormone Blockade using Sildenafil (Viagra) Letter to the Editor J. Urol., 161: 1914-1915, June 1999
Strum SB, McDermed JE, Scholz M.C., Johnson H & Tisman G: Anemia associated with androgen deprivation (AAAD) in prostate cancer patients receiving combination hormone blockade. Brit J Urol. June 1997
Gill, I., Gurglianone, P., Grunberg, S.M., Scholz, M.C., and Muggia, F.M., High Dose Intensity of Cisplatin and Etoposide in Adenocarcinoma of Unknown Primary. Anticancer Research, II, 1231, 1991
ABSTRACTS & POSTERS:
M. Scholz, R. Lam, S. Strum, H. Johnson, T. Trilling R. Jennrich. Intermittent use of Testosterone-Inactivating-Pharmaceuticals using Finasteride during Testosterone-Recovery Prolongs the Time-Off-Period. Multidisciplinary Prostate Cancer Symposium abstract #153 2005
R. Lam, M. Scholz, B. Guess, J. Mahoney, H. Johnson, T. Trilling, H. Goodman Oral bisphosphonates for the prevention of androgen deprivation therapy associated bone loss ASCO Abstract #4749 2004
M. Scholz, J. Johnson, B. Guess, R. Lam Extent of Disease on Bone Scan, Baseline Alkaline Phosphatase, and 80% Decline in PSA are the Best Indicators Predicting Long Term Survival in Men with Androgen Independent Prostate Cancer Treated with Ketoconazole and Hydrocortisone. Western AUA 2003
M. Scholz, B. Guess, R. Lam, Calcitriol Restores Docetaxol Anticancer Activity in Men with Androgen Independent Prostate Cancer Who Previously Progressed on Docetaxol. Western AUA 2003
M Scholz Guess, B. Barrios, F. Strum, S. Leibowitz, B. Low-dose Single-Agent Weekly Taxotere is Effective and Well Tolerated in Elderly Men with Prostate Cancer. ASCO Abstracts 2001
M. Seltzer, S Strum, M Scholz, A Belldegrun, N Satyamruthy, Comparison of whole body C-11 acetate and FDG PET in patients with prostate cancer Nuclear Medicine Abstracts 1999
Scholz, M., Strum, S., Mittelman, P., High-Dose Ketoconozole and Hydrocortisone for Hormone Refractory Prostate Cancer. ASCO abstracts 1999
M. Scholz, S. Strum, J. McDermed. Intermittent Androgen Deprivation (IAD) with Finasteride (F) During Induction and Maintenance Permits Prolonged Time off IAD in Localized Prostate Cancer (LPC). Presented by Dr. Scholz. The Journal of Urology, April 1999.
M. Scholz, S. Strum, Phase II Trial of Weekly Low-Dose Taxotere in the Treatment of Patients with Hormone Refractory Prostate Cancer ASCO Abstracts 1999
S. Strum, M. Scholz, A Phase II Trial of Taxotere and Emcyt for Metastatic Prostate Cancer ASCO Abstracts 1999
M. Scholz, S. Strum, L. Madsen, J. McDermed. Intermittent Androgen Deprivation (IAD) Therapy for Prostate Cancer: PSA Response on Cycle 1 Can Predict Response on Subsequent Cycles. Proceedings of ASCO Volume 18 1999, Atlanta, Georgia.
M. Scholz, S. Strum, J. McDermed, L. Madsen. Intermittent Androgen Deprivation (IAD) with Finasteride Given During the Induction and Maintenance Periods Results in Prolonged Time off IAD in Patients with Localize Prostate Cancer. Proceedings of ASCO Volume 18 1999, Atlanta, Georgia
Scholz M.C., Strum S.B, McDermed JE: A phase II trial of Taxotere (t)/Estramustine (e) combination in patients (pts) with prostate cancer (pc). Accepted for publication at the ASCO meeting May 19th, 1998, Los Angeles, CA.
Scholz M.C., McDermed JE, Strum SB: Intermittent Hormone Blockade (IHB): Optimal Induction Duration and Predictive Factors for Prolonged time Off Hormone Blockade (HB). Poster Presentation for the Xth International Congress on Hormonal Steroids, June 18th, 1998, Quebec City.
Scholz M.C., McDermed JE, Strum, SB: Combined Hormone Blockade (CHB) Induction and Finasteride Maintenance (FM) Permits Discontinuation of CHB for Prolonged Periods in Patients with Low-Volume (LV) Prostate Cancer (PC). Poster Presentation for the Xth International Congress on Hormonal Steroids, June 18th, 1998, Quebec City..
Tisman G, Strum SB, Scholz M.C., et al: Computer assisted, tumor volume-based decision making in expectant management of early stage prostate cancer. Abstract #1480, AUA 1997.
Scholz M.C., Strum SB, McDermed JE, Tisman G, Johnson H: Prolonged non-detectable PSA (NDPSA) in patients (PTS) receiving combination hormone blockade (CHB) allows for discontinuation of androgen blockade. Abstract #1478, AUA 1997.
Strum, SB, Scholz M.C. & McDermed JE: The Androgen Deprivation Syndrome: the incidence and severity in prostate cancer patients receiving hormone blockade. Accepted for poster presentation at the ASCO meeting May 19th, 1998, Los Angeles, CA.
Strum SB & Scholz M.C., Intermittent hormone blockade (IHB) in prostate cancer (PC) patients: Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment. Abstract, 7th International Congress on Anti-Cancer Treatment, February 3-6, Paris, France, 1997.
Tisman, G, Strum SB, Scholz M.C., et al: Pre-therapy prediction of the duration of post-therapy non-detectable PSA for prostate cancer patients considering intermittent combine hormonal blockade. Proc Amer Soc Clin Oncol 16: 346a, 1997.
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., nd Johnson, H., Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO). AUA abstract #1483, 1997.
Strum SB, McDermed JE, Scholz M.C.,et al: Anemia associated with androgen deprivation (AAAD) in prostate cancer (PC) patients (PTS) receiving combination hormone blockade (CHB). Proc Amer Soc Clin Oncol 16:345a, 1997.
Strum SB, McDermed J, Scholz M.C., et al: Time to non-detectable (TTND) PSA in prostate cancer (PC) patients on combination hormone blockade (CHB) predicts favorable outcomes. Proc Amer Soc Clin Oncol 16: 345a, 1997.
Strum SB, McDermed JE, Scholz M.C., Tisman G, Johnson H: Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO). J Urol 157:232 1997. (Abstract).
Tisman, G., Strum, S.B., Scholz, M.C., and McDermed, J., Pre-therapy prediction of the duration of post-therapy non-detectable PSA for prostate cancer patients considering intermittent combined hormone blockade by use of computerized neural net modeling. Abstract submitted to ASCO, 1997.
Strum, S.B., Scholz, M.C. & Strum, M. Prolonged non-detectable PSA (NDPSA) in PC patients treated with androgen deprivation may allow for discontinuation of hormone blockade. International Symposium on Recent Advances in Diagnosis & Treatment of Prostate Cancer, Quebec City, September 21-23, 1995 (Poster Presentation).
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and Johnson, H., Intermittent hormone blockade (IHB) in prostate cancer (PC) patients (PTS): Duration of non-detectable PSA (NDPSA) on androgen blockade relates to time off treatment. 7th International Chemotherapy Congress abstract, 1997.
Strum, S.B. McDermed, J.E., Scholz, M.C., Johnson, H.J., and Tisman, G., Anemia associated with androgen deprivation (AAAD) in prostate cancer (PC) patients (PTS) receiving combination hormone blockade (CHB). Abstract submitted to ASCO 1997.
Strum, S., McDermed, J., Scholz, M.C., and Tisman, G., time to non-detectable (TTND) PSA in prostate cancer (PC) patients on combination hormone blockade (CHB) predicts favorable outcomes. Abstract submitted to ASCO, 1997.
Strum, S.B., McDermed, J.E., Scholz, M.C., Tisman, G., and Johnson, H., Anemia associated with androgen deprivation in prostate cancer (PC) patients on combination hormone blockade (CHB). AUA abstract #1481, 1997.
Tisman, G., Strum, S.B., Scholz, M.C., McDermed, J.E., and Johnson, H., Computer-assisted, tumor volume-based decision making in expectant management of early stage prostate cancer. AUA abstract #1480, 1997.
Scholz, M.C., Grunberg, S., Muggia, F.M., Rosen, P., and Leishman, L., Phase I Study of TMCA. AACR Abstracts.
Scholz, M.C., Strum, S.B., McDermed, J.E., Tisman, G., and Johnson, H., Prolonged non-detectable PSA (NDPSA) in patients (PTS) receiving combination hormone blockade (CHB) allows for discontinuation of androgen blockade. AUA abstract #1478, 1997.
Scholz, M.C., Jennrich, R.I., Strum, S.B., Johnson, H., Guess, B.G., Lam, R.Y., Intermittent Use of Testosterone Inactivating Pharmaceuticals Using Finasteride Prolongs the Time Off Period. J Urol 175:1673 2006.
Clinical Trials in Progress for Prostate Cancer:
Intermittent Hormone Blockade with High dose Casodex
Thalidomide and Leukine for men with PSA relapse
Androgen replacement for prostate cancer patients with testicular failure
The impact of Dostinex on PSA doubling time
The prevention of bone loss with oral bisphosphonates
Clinically predictive factors for the early development of AIPC, clinical progression and death from prostate cancer.
Lack of benefit of local therapy for men with preexisting AIPC
Publications in Preparation:
1. High PSA nadir on hormone blockade predicts early hormone blockade failure
2. Proscar Effect in Intermittent Hormone Blockade
